More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$103064451
EPS
-1.7
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
1.902406
Previous close
$3.55
Today's open
$3.58
Day's range
$3.55 - $3.78
52 week range
$3.33 - $8.74
show more
CEO
Shalabh Gupta
Employees
21
Headquarters
Mountain View, CA
Exchange
NASDAQ Capital Market
Shares outstanding
27855257
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
MOUNTAIN VIEW, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.
GlobeNewsWire • Nov 16, 2026

Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
MOUNTAIN VIEW, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026, at 2:30 p.m. ET.
GlobeNewsWire • Nov 4, 2026

Levi & Korsinsky Reminds Unicycive Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 2, 2026 - UNCY
A securities class action alleges Unicycive Therapeutics resubmitted its oxylanthanum carbonate New Drug Application without ever inspecting its third-party manufacturer's facility for cGMP compliance. Pension funds, asset managers, and other fiduciaries that held UNCY during the Class Period may wish to evaluate lead plaintiff options. A securities class action alleges Unicycive Therapeutics resubmitted its oxylanthanum carbonate New Drug Application without ever inspecting its third-party manufacturer's facility for cGMP compliance. Pension funds, asset managers, and other fiduciaries that held UNCY during the Class Period may wish to evaluate lead plaintiff options.
GlobeNewsWire • Nov 2, 2026

Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
New class action for Unicycive (UNCY) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/2/2026
GlobeNewsWire • Nov 2, 2026

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
NEW YORK--(BUSINESS WIRE)---- $UNCY #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Geor.
Business Wire • Nov 2, 2026

DEADLINE ALERT for Hims & Hers Health, Inc. (HIMS), Unicycive Therapeutics, Inc. (UNCY), and Papa John's International, Inc. (PZZA): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions
Investors in Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., and Papa John's International, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions Investors in Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., and Papa John's International, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions
GlobeNewsWire • Nov 2, 2026

UNCY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 31, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Newsfile Corp • Oct 31, 2026

UNCY URGENT DEADLINE: Unicycive Therapeutics, Inc. Investors Have Until November 2nd to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff Role
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options
GlobeNewsWire • Oct 31, 2026

Unicycive Therapeutics: 95% Upside Priced Against A Wall Of Dilution And Regulatory Risk
Unicycive Therapeutics is rated Buy, with a risk-adjusted fair value of $6.97 per share, nearly 95% upside from current prices. UNCY's lead drug, OLC, targets hyperphosphatemia in CKD dialysis patients, with a PDUFA date set for March 25, 2027, after resolving manufacturing issues. Despite $61.4M in cash, a likely capital raise for commercialization could possibly as much as double share count, heavily diluting shareholders.
Seeking Alpha • Oct 31, 2026

UNCY CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 30, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Newsfile Corp • Oct 30, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Unicycive Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.